HIGH-DOSE CHEMOTHERAPY FOR PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM. INTERIM RESULTS OF THE CNS-2015 PROTOCOL

Introduction. Induction chemotherapy (CT) for primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) is based on the use of methotrexate in high doses. An optimal consolidation strategy involves high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (auto-HSCT). The most effective conditioning regimen comprises a combination of chemotherapy agents including thiotepa.

Aim. To present the authors’ experience of applying auto-HSCT/TBC in patients with primary DLBCL of the CNS.

Methods. The prospective study CNS-2015 was carried out among 20 patients aged 20–52 years (median 42 years old) from 2015 to 2019. The male/female ratio came to 13/7. The somatic status of 17 (85 %) patients was 0–1 on the ECOG scale. Only 3 (15 %) patients showed the somatic status of 4 points. According to the criteria of the MSKCC prognostic system, 18 (90 %) and 2 (10 %) patients were assigned to the low-risk and medium-risk groups, respectively.

Results. All patients included in the study received 3–5 cycles of chemotherapy with high doses of methotrexate, vincristine, procarbazine and rituximab (R-MPV), as well as underwent auto-HSCT following TBC-based conditioning regimen (thiotepa, busulfan, cyclophosphamide). Prior to auto-HSCT, 15 and 5 out of 20 patients having completed induction chemotherapy achieved complete remission and partial remission, respectively. Following auto-HSCT, complete remission was achieved in 5 patients with an initial partial response to treatment. All patients underwent temozolomide maintenance therapy for 2 years. With a median follow-up of 17 (1–46) months, 18 patients are alive and in remission. Two patients, who relapsed 4 and 5 months after auto-HSCT and achieved no response to the second line of chemotherapy and radiation therapy, died 24 and 26 months after auto-HSCT.

Conclusion. R-MPV is an effective treatment for patients with primary DLBCL of CNS, which is not accompanied by severe toxicity. The use of high-dose chemotherapy with TBC allows a high remission rate to be achieved. The mortality associated with treatment in the group of patients included in the study came to 0 %.

1. Gubkin A.V., Zvonkov Е.Е., Kremenetskaya A.М. et al. Primary lymphoproliferative diseases of the central nervous system. Clinicheskaya Oncohematologiya. Moscow. 2008; 1(4): 323–32 (In Russian).

2. Gubkin A.V., Zvonkov Е.Е., Kremenetskaya A.М. et al. Primary lymphoproliferative diseases of the central nervous system. Therapevticheskiy arkhiv. 2009; 81(7): 85–91 (In Russian).

3. Vorobyev A.I., Kremenetskaya А.М. Atlas of Tumors of the Lymphatic System. Moscow: Niyuamed; 2007: 292.

4. Zvonkov Е.Е., Koroleva D.А., Gabeeva N.G. et al. The research protocol for the treatment in patients of primary central nervous system lymphoma (CNS-2015). Diagnostic algorithms and protocols for treatment of diseases of the blood system. Moscow. 2018; 2: 609–22 (In Russian).

5. Grommes C., DeAngelis L. M. Primary CNS Lymphoma. J. Clin. Oncol. 2017; 35(21): 2410–18. DOI: 10.1200/JCO.2017.72.7602

6. Fox C.P., Phillips E.H., Smith J. et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br. J. Haematol. 2019; 184(3): 348–63. DOI: 10.1111/bjh.15661

7. Paydas S. Primary central nervous system lymphoma: essential points in diagnosis and management. Med. Oncol. 2017; 34(61). DOI: 10.1007/s12032-017- 0920-7

8. Löw S., Han C.H., Batchelor T.T. Primary central nervous system lymphoma. Therapeutic Advances in Neurological Disorders. 2018; 11: 1–16. DOI: 10.1177/1756286418793562

9. Sethi T.K., Reddy N.M. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leuk. Lymphoma. 2019; 60(1): 6–18. DOI: 10.1080/10428194.2018.1466296

10. Grommes C., Rubenstein J.L., DeAngelis L.M. et al. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019; 21(3): 296–305. DOI: 10.1093/neuonc/noy192

11. Nakamura T., Yamashita S., Fukumura K. et al. Genomewide DNA methylation profi ling identifi es primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. Acta Neuropathol. 2017; 133(2): 321–4. DOI: 10.1007/s00401-016-1664-8

12. Mareschal S., Pham-Ledard A., Viailly P.J. et al. Identifi cation of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing. J Invest. Dermatol. 2017; 137: 1984–94. DOI: 10.1016/j. jid.2017.04.010

13. Fontanilles M., Marguet F., Bohers É. et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017; 8(29): 48157–68. DOI: 10.18632/oncotarget.18325

14. Brunn A., Nagel I., Montesinos-Rongen M. et al. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol. 2013; 126: 603–5. DOI: 10.1007/s00401-013-1169-7

15. Galanina N., Bejar R., Choi M. et al. Comprehensive genomic profi ling reveals diverse but actionable molecular portfolios across hematologic malignancies: implications for next generation clinical trials. Cancers. 2018; 11(1). DOI: 10.3390/cancers11010011

16. Munch-Petersen H. D., Asmar F., Dimopoulos K. et al. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathol. Commun. 2016; 4: 40. DOI: 10.1186/s40478-016-0307-6

17. Hickmann A.K., Frick M., Hadaschik D. et al. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas. BMC Cancer. 2019; 19: 192. DOI: 10.1186/s12885-019-5394-x

18. Nayyar N., White M. D., Gill C.M. et al. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood. 2019; 3: 3. DOI: 10.1182/bloodadvances.2018027672

19. De Mattos-Arruda L., Mayor R. et al. Cerebrospinal fl uid-derived circulating tumour DNA better represents the genomic alterations of brain tumors than plasma. Nat. Commun. 2015; 6: 8839. DOI: 10.1038/ncomms9839

20. Nosrati A., Monabati A., Sadeghipour A. et al. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type. Ann. Hematol. 2019; 98(1):169–73. DOI: 10.1007/s00277-018-3498-z

21. Chapuy B., Roemer G.M., Stewart C. et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016; 127(7): 869–81. DOI: 10.1182/blood-2015-10-673236

22. Cai Q., Fang Yu, Young K.H. Primary central nervous system lymphoma: molecular pathogenesis and advances in Treatment. Transl. Oncol. 2019; 12: 523– 38. DOI: 10.1016/j.tranon.2018.11.011

23. Holdhoff M., Ambady P., Abdelaziz A. et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014; 83: 235–39. DOI: 10.1212/WNL.0000000000000593

24. Mendez J. S., Grommes C. Treatment of primary central nervous system lymphoma: from chemotherapy to small molecules. Am. Soc. Clin. Oncol. Educ Book. 2018; 23(38): 604–15. DOI: 10.1200/EDBK_200829

25. Abramson J.S., McGree B., Noyes S. et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N. Engl. J. Med. 2017; 377(8): 783–4. DOI: 10.1056/NEJMc1704610

26. Omuro A., Correa D.D., DeAngelis L.M. et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015; 125: 1403–10. DOI: 10.1182/ blood-2014-10-604561

27. Scordo M., Bhatt V., Hsu M. et al. A comprehensive assessment of toxicities in patients with CNS lymphoma undergoing autologous stem cell transplantation using Thiotepa, Busulfan and Cyclophosphamide conditioning. Biol Blood Marrow Transplant. 2017; 23(1): 38–43. DOI: 10.1016/j.bbmt.2016.09.024

28. DeFilipp Z., Li S., El-Jawahri A. et al. High-Dose chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in fi rst complete remission. Cancer. 2017; 123(16): 3073–9. DOI: 10.1002/cncr.30695

29. Cheng T., Forsyth P., Chaudhry A. et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 2003; 31: 679–85. DOI:10.1038/sj.bmt.1703917

30. Chen Yi-Bin, Batchelor T., Li S. et al. Phase 2 Trial of High-Dose Rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by Non-Hodgkin lymphoma. Cancer. 2015; 121(2): 226–33. DOI: 10.1002/cncr.29023

31. Houillier C., Taillandier L., Dureau S. et al. Radiotherapy or autologous stemcell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J. Clin. Oncol. 2019; 37: 823–33. DOI: 10.1200/JCO.18.00306

32. Alimohamed N., Daly A., Owen C. et al. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leuk. Lymphoma. 2012; 53(5): 862–67. DOI: 10.3109/10428194.2011.633250

33. Hu B. A Tale of two eras: The story of autologous stem cell transplantation with and without thiotepa for primary central nervous system lymphoma. Biol. Blood Marrow Transplantat. 2019; 25(5): 141–2. DOI: 10.1016/j.bbmt.2019.03.014

34. Terziev D., Hutter B., Klink B., et al. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. Eur. J. Haematol. 2018; 101(1): 115–8. DOI: 10.1111/ ejh.13072

35. Rubenstein J.L., Geng H., Vu K. et al. Maintenance Lenalidomide in Primary CNS Lymphoma. Ann Oncol. 2019; 30(8):1397–8. DOI: 10.1093/annonc/ mdz142

36. Glass J., Won M., Schultz C.J. et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by wholebrain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. J. Clin. Oncol. 2016; 34(14): 1620–5. DOI: 10.1200/JCO.2015.64.8634

37. Oken M., Creech R., Tormey D. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649–55.

38. ht tps://w w w.eor tc .be/ser vices/doc/c tc/CTC AE _v5 _Q uick _ Reference_5x7.pd

39. Wen P.Y., Chang S. M., Van den Bent M.J. et al. Response Assessment in Neuro-Oncology Clinical Trials. J. Clin. Oncol. 2017; 35(21): 2439–49. DOI: 10.1200/JCO.2017.72.7511

40. Russell S. and Rubinstei L. J. Pathology of Tumours of the Nervous System. J. Pathol. 1989; 158: 359–60. DOI: 10.1002/path.1711580413

41. Qian L., Tomuleasa C., Florian I. et al. Advances in the treatment of newly diagnosed primary central nervous system lymphomas. Blood 2017; 52: 159–66. DOI: 10.5045/br.2017.52.3.159

42. Angelov L., Doolittle N.D., Kraemer D.F. et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J. Clin. Oncol. 2009; 27(21): 3503–9. DOI: 10.1200/JCO.2008.19.3789

43. Gavrilovic I.T., Hormigo A, Yahalom J. et al. Long-Term Follow-Up of HighDose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma. J. Clin. Oncol. 2006; 24(28): 4570–4. DOI: 10.1200/JCO.2006.06.6910

44. Schorb E., Fox C.P., Fritsch K. et al. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant. 2017; 52(8): 1113–9. DOI: 10.1038/bmt.2017.23

45. Gaut D., Schiller G.J. Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature. International J. Hematol. 2019; 109(3): 260–77. DOI: 10.1007/s12185-019-02594-1

46. Alnahhas I., Jawish M., Alsawas M. et al. Autologous stem cell transplant for primary central nervous system lymphoma: A systematic review and metaanalysis. Clin. Lymphoma Myeloma Leuk. 2019; 19(3): 129–41. DOI: 10.1016/j. clml.2018.11.018

47. Dholaria B.R., Kumar A., Azzuqua A. et al. Autologous stem cell transplantation in central nervous system lymphoma: A multicenter retrospective series and a review of the literature. Clin. Lymphoma Myeloma Leuk. 2019; 19(6): 273–80. DOI: 10.1016/j.clml.2019.02.013

48. Soussain C., Suzan F., Hoang-Xuan K. et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol. 2001; 19: 742–9. DOI: 10.1200/JCO.2001.19.3.742

49. Sellner L., Boumendil A., Finel H. et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant. 2016; 51: 212–8. DOI: 10.1038/bmt.2015.273

50. Osmani A.H., Masood N. Temozolomide for relapsed primary CNS lymphoma. J Coll Physicians Surg. Pak. 2012; 22(9): 594–5. DOI: 09.2012/JCPSP.594595

51. Kassa C., Reményi P., Sinkó J. et al. Successful nivolumab therapy in an allogeneic stem cell transplant child with post‐transplant lymphoproliferative disorder. Pediatr. Transplant. 2018; 22(8): 13302. DOI: 10.1111/petr.13302

52. Graham M.S., DeAngelis L. M. Improving outcomes in primary CNS lymphoma. Best Pract Res. Clin. Haematol. 2018; 31: 262–9. DOI: 10.1016/j. beha.2018.07.006

53. Nayak L., Iwamoto F. M, LaCasce A. et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017; 129(23): 3071–3. DOI: 10.1182/blood-2017-01-764209

54. Grommes C., Nayak L., Tun H.W., Batchelor T.T. Introduction of novel agents in the treatment of Primary CNS Lymphoma. Neuro-Oncol. 2018; 21(3): 306–13. DOI: 10.1093/neuonc/noy193

55. Chamoun K., Choquet S., Boyle E. et al. Ibrutinib monotherapy in relapsed/ refractory CNS lymphoma: A retrospective case series. Neurology. 2017; 88(1): 101–2. DOI: 10.1212/WNL.0000000000003420

56. Houillier C., Choquet S., Touitou V. et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology. 2015; 84(3): 325–6. DOI: 10.1212/WNL.0000000000001158

57. Atilla E., Sahin U., Atilla P.A. et al. Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible? Hematol. Oncol. Stem. Cell Ther. 2018; 1658–3876(18): 30025–6. DOI: 10.1016/j.hemonc.2018.02.001

58. Varadi G., Or R., Kapelushnik J. et al. Graft-Versus-Lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk. Lymph. 1999; 34(1–2): 185–90. DOI: 10.3109/10428199909083396